Cg Oncology, Common Stock Today
| CGON Stock | 33.95 0.48 1.43% |
Performance0 of 100
| Odds Of DistressOver 53
|
CG Oncology, is selling at 33.95 as of the 26th of November 2024; that is 1.43 percent up since the beginning of the trading day. The stock's open price was 33.47. CG Oncology, has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for CG Oncology, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of January 2023 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of January 2024 | Category Healthcare | Classification Health Care |
CG Oncology, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 66.64 M outstanding shares of which 5.6 M shares are currently shorted by private and institutional investors with about 4.11 trading days to cover. More on CG Oncology, Common
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CGON Stock Highlights
| Chairman CEO | Arthur Kuan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt LevelsCG Oncology, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CG Oncology,'s financial leverage. It provides some insight into what part of CG Oncology,'s total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CG Oncology, Common (CGON) is traded on NASDAQ Exchange in USA. It is located in 400 Spectrum Center Drive, Irvine, CA, United States, 92618 and employs 61 people. CG Oncology, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.4 B. CG Oncology, Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 66.64 M outstanding shares of which 5.6 M shares are currently shorted by private and institutional investors with about 4.11 trading days to cover.
CG Oncology, generates negative cash flow from operations
Check CG Oncology, Probability Of Bankruptcy
Ownership AllocationCG Oncology, Common secures a total of 66.64 Million outstanding shares. The majority of CG Oncology, Common outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in CG Oncology, Common to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in CG Oncology, Common. Please pay attention to any change in the institutional holdings of CG Oncology, as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CGON Ownership Details
CG Oncology, Historical Income Statement
CGON Stock Against Markets
CG Oncology, Corporate Management
| Bing Kung | Vice Development | Profile | |
| Joshua Patterson | General Officer | Profile | |
| Swapnil Bhargava | Chief Officer | Profile | |
| Vijay MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.036 | Quarterly Revenue Growth 1.727 |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.